(MGNX) MacroGenics, Inc. BCG Matrix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(MGNX) MacroGenics, Inc. Complete Analysis Pack
Visual. Strategic. Downloadable.
This MacroGenics, Inc. BCG Matrix helps you quickly see how the company’s products or business units may be positioned across Stars, Cash Cows, Question Marks, and Dogs for strategy and investment planning. The page already shows a real preview of the actual analysis, so you can review the format and content before buying. Purchase the full version to get the complete ready-to-use report.
Stars
MGC018, Phase 2 B7-H3 ADC
MGC018 is one of MacroGenics, Inc.’s top growth bets in solid tumors: a Phase 2 B7-H3 ADC aimed at a target linked to more than 10 tumor types, while global ADC sales are projected to top $20 billion by 2030.
B7-H3 remains a high-interest oncology target, so a clean readout could drive faster partnering and better upfront and milestone terms.
That makes MGC018 a clear "Star" in the BCG Matrix, with high market potential and rising strategic value.
Enoblituzumab, B7-H3 antibody
Enoblituzumab targets B7-H3, a solid-tumor antigen linked to high unmet need and broad combo use across immuno-oncology. B7-H3 remains a growth area: the global oncology drug market was about $220 billion in 2025, and B7-H3 assets are still early in the cycle. If late-stage data stay positive, MacroGenics, Inc. could push this into a Star role and make it a lead franchise asset.
MGD024, CD123 x CD3 DART
MGD024, a CD123 x CD3 DART, fits a "Star" role because it targets hematologic malignancies where unmet need stays high, especially AML, which still drives about 20,000 new U.S. cases a year. CD123 T-cell engagers remain a fast-growing class, and clinical wins could lift MacroGenics' pipeline value fast. Strong data here could shift the asset from optionality to a core growth driver.
IMGC936, ADAM9 ADC
IMGC936, ADAM9 ADC is a newer solid-tumor asset, so it fits MacroGenics, Inc.'s high-upside but early-risk "Star" profile. ADCs remain one of oncology’s fastest-growing classes, with steady 2025-2026 deal flow and new readouts. If IMGC936 shows clear efficacy or safety separation, the solid-tumor market opportunity can be large.
- Newer ADC, broad solid-tumor angle.
- High growth class, high readout risk.
- Differentiation is the key value driver.
Retifanlimab, partnered commercial asset
Retifanlimab is MacroGenics, Inc.’s strongest near-term monetization path outside MARGENZA because Incyte already commercializes Zynyz in approved immuno-oncology use. That gives MacroGenics exposure to an active market now, not just pipeline optionality. Any label expansion would lift growth, since the asset already has a cleared launch base.
- Partnered, approved, and revenue-linked
- Best near-term upside beyond MARGENZA
- Label expansion would boost growth
MacroGenics’ Star Assets Could Drive Major Oncology Upside
MacroGenics, Inc.’s Stars are the pipeline assets with the clearest high-growth pull: MGC018, Enoblituzumab, MGD024, and IMGC936. ADC sales are projected to top $20B by 2030, the global oncology drug market was about $220B in 2025, and AML still drives about 20,000 new U.S. cases a year, so each asset has real upside if data stay strong.
| Asset | Why it fits Star |
|---|---|
| MGC018 | Phase 2 B7-H3 ADC; broad solid-tumor demand |
| MGD024 | CD123 x CD3; AML growth tied to high need |
What is included in the product
Detailed Word Document
MacroGenics’ BCG Matrix maps its pipeline by growth and share, showing where to invest, hold, or cut.
Editable Excel File
One-page BCG Matrix for MacroGenics to quickly spot stars, cash cows, and divestment risks.
Reference Sources
Gives a trusted source trail for MacroGenics, Inc. that strengthens credibility and speeds investor decision-making.
Cash Cows
MARGENZA, only approved MacroGenics product
MARGENZA is MacroGenics’ only approved product, so it is the clearest cash cow in the portfolio. Approved in 2020, it gives the company real commercial presence and recurring product revenue, even if sales remain modest. In 2025, that approved status still matters most: it is the only marketed asset with direct revenue exposure.
Zynyz royalties, retifanlimab
Zynyz royalties from retifanlimab give MacroGenics, Inc. a cleaner cash stream than pipeline R&D, because approved sales can turn into royalty income with no extra clinical spend. Zynyz was FDA-approved in 2023 for metastatic or recurrent locally advanced Merkel cell carcinoma, and each new sales dollar can feed MacroGenics, Inc. through its collaboration economics. It is one of the few lower-risk inflows tied to a marketed asset.
Incyte collaboration funding
Incyte collaboration funding is a cash cow for MacroGenics, Inc. because partner capital helps pay for development and cuts MacroGenics’ own cash burn. Incyte also shares program risk, so MacroGenics can keep advancing pipeline assets without funding the full bill alone. This is classic cash-supporting collaboration economics.
Janssen collaboration funding
Janssen collaboration funding is a Cash Cow for MacroGenics, Inc. because partner receipts help pay R&D costs without needing broad product sales. For a small biotech, that steady collaboration cash is more reliable than speculative pipeline upside.
- Offsets R&D burn
- Supports a lean biotech model
- Steady, non-commercial cash
Zai Lab and I-Mab partnerships
Zai Lab and I-Mab give MacroGenics, Inc. non-dilutive upside because the company keeps regional or strategic rights economics without funding the full buildout. These deals can trigger milestones and royalties, so they act like cash-generating assets even before product sales scale.
- Milestones add near-term cash.
- Shared development cuts spend.
- Regional rights limit dilution.
MARGENZA Powers MacroGenics; Partnerships Fuel the Rest
MARGENZA is MacroGenics, Inc.’s only approved product, so it remains the main cash cow in 2025. Zynyz royalties add lower-risk inflow from an approved asset, while Incyte and Janssen collaboration receipts help fund R&D and cut cash burn. Zai Lab and I-Mab can also bring milestones and royalties without full buildout spend.
| Asset | Cash role |
|---|---|
| MARGENZA | Product revenue |
| Zynyz | Royalties |
| Incyte | Partner funding |
| Janssen | Partner funding |
Preview Before You Purchase
MacroGenics, Inc. Reference Sources
The MacroGenics, Inc. BCG Matrix preview you see here is the exact same document you’ll receive after purchase. No demo content or watered-down version—just the full, ready-to-use file. It’s formatted for clear strategic review and immediate practical use. Download it once, and it’s yours to edit, print, or present.
Dogs
MGD014, HIV DART
MGD014, HIV DART sits in MacroGenics, Inc.'s Dogs bucket because HIV is outside its core oncology focus. The program is a DART bispecific for HIV, but it does not drive the company’s main growth path. With MacroGenics, Inc. still centered on cancer assets, MGD014 looks like a niche R&D bet with limited commercial scale.
MGD020, HIV DART
MGD020, HIV DART is a non-core HIV asset for MacroGenics, and it fits Dogs in the BCG Matrix. The HIV antiretroviral market is mature, heavily genericized, and crowded, while MacroGenics' core spend and pipeline remain centered on oncology. That weak fit lowers strategic value and makes capital use harder to justify.
Teplizumab, type 1 diabetes
Teplizumab sits outside MacroGenics, Inc.'s core cancer franchise, so it does not look like a strategic growth engine. The asset was FDA approved in 2022 for delaying type 1 diabetes, but it has not shown clear scale or material pull for MacroGenics. It ties up attention with limited fit, which is why it belongs in Dogs.
PRV-3279, autoimmune DART
PRV-3279 sits in a crowded autoimmune DART field, where many rivals chase the same biology and clinical readouts, so execution risk stays high. MacroGenics, Inc. has clearer value drivers in oncology, while this program still has no approved label or near-term revenue path. That makes PRV-3279 a classic Dogs asset in the BCG view.
- High crowding, high trial risk
- Weak near-term commercial visibility
- Better capital use in oncology
Legacy non-core programs
Legacy non-core programs at MacroGenics, Inc. are older assets that can still burn cash without building meaningful market share, so they sit well behind the company’s lead oncology programs. In 2025, MacroGenics kept capital focused on higher-value cancer assets, making these programs natural candidates for minimal spend or out-licensing.
- Low strategic priority
- Cash drag risk
- Better fit for licensing
- Focus stays on oncology leads
MacroGenics’ Dogs: Non-Core Assets, Low Near-Term Value
MacroGenics, Inc.'s Dogs are mainly non-core HIV and autoimmune programs, plus legacy assets that do not fit its oncology-led strategy. They face weak commercial pull, high crowding, and no clear near-term revenue path, so capital use stays low-priority.
| Asset | Dogs signal |
|---|---|
| MGD014 | Non-core HIV, limited scale |
| PRV-3279 | Crowded, no approved label |
Question Marks
Lorigerlimab, PD-1 x CTLA-4
Lorigerlimab is a high-upside immuno-oncology question mark for MacroGenics, Inc. because PD-1 and CTLA-4 remain a huge checkpoint market, but rivals like Bristol Myers Squibb, Merck, and Roche make the bar very high. It needs clear efficacy and safety data to justify heavier spend, since dual-checkpoint combos can add toxicity and development risk. In BCG terms, it is worth watching, but only strong late-stage data can move it out of the question mark box.
Tebotelimab, PD-1 x LAG-3
Tebotelimab sits in a growing LAG-3 checkpoint space, now validated by the 2022 FDA approval of relatlimab/nivolumab.
But MacroGenics, Inc. still has unproven share here because tebotelimab is not yet a commercial product, so revenue impact remains zero for now.
That makes it a classic invest-or-pass question: high upside if data land well, but still a Question Mark in the BCG Matrix.
MGC018 expansion, new solid tumors
MGC018’s move into additional solid tumors could lift MacroGenics, Inc.’s addressable market well beyond one niche, since solid tumors make up most oncology cases worldwide.
But the asset still needs broader clinical proof across new cohorts, with safety and response durability key.
If later-stage data hold up, MGC018 could shift from a question mark toward star status in the BCG matrix.
Enoblituzumab expansion, combination trials
Enoblituzumab is still a Question Mark in MacroGenics, Inc.'s BCG mix: it has higher-upside combinations in bladder, head and neck, and other solid tumors, but its market share is still unproven. MacroGenics reported no approved enoblituzumab revenue, so the program lives or dies on clinical data and partner interest. To avoid drifting toward Dog status, it needs clear response data and a sharper profile versus PD-1/PD-L1-based regimens.
- Big upside if combinations work
- No proven share or sales yet
- Data, not hype, drives value
- Differentiation is the key risk
IMGC936 expansion, basket studies
IMGC936 fits the Question Marks bucket: if basket studies show proof-of-concept, broader testing could open value across several solid tumors. The market is large, but current penetration is still low, so adoption depends on clear clinical signal. For MacroGenics, Inc., the key gate is not demand, it is whether the data can prove enough activity to justify expansion.
- Broad solid-tumor upside
- Low current market penetration
- Proof-of-concept is the gate
MacroGenics’ Question Marks: High Upside, No Revenue Yet
MacroGenics, Inc.’s Question Marks are high-potential but unproven programs: lorigerlimab, tebotelimab, MGC018, enoblituzumab, and IMGC936. They sit in large oncology markets, but none has commercial sales, so value depends on late-stage data, safety, and partner interest. As of 2025, MacroGenics, Inc. still had no approved product revenue from these assets.
| Asset | BCG read | Key gate |
|---|---|---|
| Lorigerlimab | Question Mark | Dual-checkpoint data |
| Tebotelimab | Question Mark | LAG-3 proof |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.